Brazil/Merck: compulsory license
Thanks to expert group member Edson Beas Rodrigues Jr of IDCID Brazil for prompt details of this.
Merck is not surprisingly none too happy at Brazil's decision to move to issue a compulsory licence in respect of AIDS treatment Stocrin (efavirenz). http://www.pharmabiz.com/article/detnews.asp?articleid=38702§ionid= There had been discussions but so far these have not reached a mutually acceptable conclusion.
As is well established, TRIPS and the Doha declaration permit compulsory licensing - sometimes. As ever it seems to come down to money, with Merck considering Brazil able to pay more than it is offering: to what extent should a country's (relative?) economic status come into whether compulsory licensing is acceptable. A balanced report from Aidsmap here: http://www.aidsmap.com/en/news/0550CE62-3F90-4603-932C-EF69E1B4485D.asp
Merck is not surprisingly none too happy at Brazil's decision to move to issue a compulsory licence in respect of AIDS treatment Stocrin (efavirenz). http://www.pharmabiz.com/article/detnews.asp?articleid=38702§ionid= There had been discussions but so far these have not reached a mutually acceptable conclusion.
As is well established, TRIPS and the Doha declaration permit compulsory licensing - sometimes. As ever it seems to come down to money, with Merck considering Brazil able to pay more than it is offering: to what extent should a country's (relative?) economic status come into whether compulsory licensing is acceptable. A balanced report from Aidsmap here: http://www.aidsmap.com/en/news/0550CE62-3F90-4603-932C-EF69E1B4485D.asp
posted by Dr Abbe Brown at 9:09 am
BlogItemURL>
Link
0 comments
